Driven by 20% organic revenue growth in its headset division, GN issued its third quarter corporate report which showed 12% organic revenue growth and an EBITA margin increased to 18.0%. GN’s earnings per share increased by 10% compared to the same period last year.
Read More
According to HIA statistics, the US hearing aid market has experienced sales gains of 5.9% and may exceed 4 million hearing aid units dispensed by the end of 2018. Here’s a summary of the US hearing industry statistics through the third quarter of this year, including a look at the most-common styles of hearing aids sold.
Read More
Overall, the findings of this study demonstrate that the two new CROS/BiCROS systems from Signia—the Pure 312 Nx CROS with Narrow directionality and the Silk Nx CROS—provide a superior solution to the daily listening problems encountered by people with SSD.
Read More
On October 31, Sandy Brandmeier officially joined Sonova USA and will work alongside current US Wholesale President Jan Metzdorff, who has been on a limited assignment in North America since August 2016. Over the next 5 months, both will work in concert to ensure a seamless transition until Brandmeier takes over full responsibility as President of Sonova Wholesale US on April 1, 2019.
Read More
The 2018 Academy of Doctors of Audiology (ADA) Convention had the theme, “Bolder than Ever,” and lived up to it with 3 days of excellent seminars and events in Orlando, Fla, on October 22-24.
Read More
GN Hearing CEO Anders Hedegaard has resigned after accepting a position as CEO in another company outside of the hearing industry. Marcus Desimoni will act as interim CEO of GN Hearing, in parallel with his role as CFO of GN Store Nord and GN Hearing, until a new CEO for GN Hearing is appointed.
Read More
John Hansen, PhD, professor of electrical and computer engineering at The University of Texas at Dallas, and his colleagues have developed CCi-MOBILE, a research platform that enables easy development and evaluation of sound processing algorithms/strategies with cochlear implants, as well as hearing aids.
Read More
Before jumping to the conclusion that any PSAP and/or future OTC hearing device would be suitable for the many different types of hearing losses, we need to look at their coupler and real-ear performance data. This study by Adam Voss, Kristi Oeding, AU Bankaitis, John Pumford, and Michael Valente suggests current PSAPs are suitable for mild losses only.
Read More
The FDA has concluded that the Bose Hearing Aid should be classified as a Class II device under the generic name “self-fitting air-conduction hearing aid,” according to an October 5 letter from the Agency. Accordingly, Bose is free to market the device immediately subject to general provisions and special controls required by FDA. Subsequent applications for a self-fitting hearing aid will need to undergo premarket notification requirements, according to the Agency.
Read More
In a conversation with Bose Hearing leaders this week, it became clear that Bose would be borrowing some aspects of their Hearphone technology but not using it as the Bose Hearing Aid. The company views the de novo application as being primarily focused on direct-to-consumer (DTC) distribution, although they do have an interest in the professional channel, and the product is still some ways from becoming available to consumers.
Read More
With the start of the EUHA Congress in Hannover, Germany, GN ReSound has announced a new partnership with Google that will offer a full spectrum of direct streaming to hearing aids from Android devices, and the company is showcasing its “premium-plus” hearing aid, ReSound LiNX Quattro,™ which was launched in August.
Read More
With a new level of sound quality, direct connectivity to IOS and Android as well as virtually all Bluetooth devices, hands-free phone use, rechargeability with a full day of streaming, and apps that feature remote fine-tuning and a live voice-to-text transcription, the new Phonak Marvel RIC sounds like it could be a superhero.
Read More
The FDA’s recent granting of de novo status for the self-fit Bose Hearing Aid may open the door to a new era of hearing aid technology and dispensing. Unlike an “OTC hearing device,” there will likely be a “self-fitting category” within the current FDA Class I and Class II hearing aid classifications.
Read More
The FOCAS tool is designed to: 1) Actively seek input from both the client and family during the hearing needs and goal setting process; 2) Assess whether these are near- or far-field situations, and 3) Help to determine the optimal solutions for each. This paper by David Crowhen, MAud, and Bettina Turnbull, MAud, describes the survey results, rationale for, and how to use the FOCAS tool.
Read More
The FDA has approved the Bose Hearing Aid as the first self-fit hearing aid under the Agency’s De Novo premarket review pathway used for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.
Read More